- Trastuzumab Exposure during Pregnancy with Invasive Breast Cancer
-
Min JW, Kang YD
- KMID: 2409129
- Perinatology.
- 2017 Dec;28(4):184-186.
- doi: 10.14734/PN.2017.28.4.184
Trastuzumab is a monoclonal antibody used for the treatment of human epidermal growth factor receptor-2 positive breast cancer. There is a little information in the literature regarding the safe use... -
- CITED
-
- Close
- SHARE
-
- Close
- Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
-
Park WY, Kim HJ, Kim K, Bae SB, Lee N, Lee KT, Won JH, Park HS, Lee SC
- KMID: 2454364
- Cancer Res Treat.
- 2016 Apr;48(2):843-847.
- doi: 10.4143/crt.2014.234
Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on... -
- CITED
-
- Close
- SHARE
-
- Close
- Psoriasis Induced by Trastuzumab (Herceptin(R))
-
Kim DH, Jeong NJ, Im M, Lee Y, Seo YJ, Lee JH
- KMID: 2171795
- Ann Dermatol.
- 2013 May;25(2):229-231.
- doi: 10.5021/ad.2013.25.2.229
Trastuzumab (Herceptin), a humanized monoclonal antibody, is a cancer drug developed to target the human epidermal receptor (HER) 2, which is overexpressed in some cancer cells. Cutaneous side effects, such... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk of Trastuzumab-Related Cardiotoxicity in Early Breast Cancer Patients: A Prospective Observational Study
-
Xue J, Jiang Z, Qi F, Lv S, Zhang S, Wang T, Zhang X
- KMID: 2176128
- J Breast Cancer.
- 2014 Dec;17(4):363-369.
- doi: 10.4048/jbc.2014.17.4.363
PURPOSE: In the present study, we investigated the incidence of cardiotoxicity within 5 years of trastuzumab treatment and evaluated potential risk factors in clinical practice. METHODS: The study cohort included 415... -
- CITED
-
- Close
- SHARE
-
- Close
- Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
-
El-Enbaby , El Moneim , El atti Khedr GA, Elwany YM
- KMID: 2432608
- Korean J Clin Oncol.
- 2018 Dec;14(2):108-115.
- doi: 10.14216/kjco.18019
PURPOSE: This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
-
Kim IH, Lee JE, Youn HJ, Song BJ, Chae BJ
- KMID: 2379402
- J Breast Cancer.
- 2017 Mar;20(1):82-90.
- doi: 10.4048/jbc.2017.20.1.82
PURPOSE: We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment. METHODS: The medical records of 228 patients who underwent... -
- CITED
-
- Close
- SHARE
-
- Close
- Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection
-
Prieto M, Gastaca M, Ruiz P, Ventoso A, Palomares , Perfecto A, Valdivieso A
- KMID: 2464332
- Ann Hepatobiliary Pancreat Surg.
- 2019 Nov;23(4):403-407.
- doi: 10.14701/ahbps.2019.23.4.403
Surgery is the only treatment for biliary tract cancer with long term survival. Unfortunately, most patients are diagnosed at stage IV with distant metastases. In these circumstances, life expectancy is... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and Tolerability of Docetaxel, Cyclophosphamide, and Trastuzumab Compared to Standard Trastuzumab-Based Chemotherapy Regimens for Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
-
Jitawatanarat P, O'Connor T, Kossoff EB, Levine EG, Chittawatanarat K, Ngamphaiboon N
- KMID: 2176127
- J Breast Cancer.
- 2014 Dec;17(4):356-362.
- doi: 10.4048/jbc.2014.17.4.356
PURPOSE: We evaluated the tolerability and cardiac safety of docetaxel, cyclophosphamide, and trastuzumab (TCyH) for the treatment of early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer and compared... -
- CITED
-
- Close
- SHARE
-
- Close
- Percutaneous Pericardiostomy and Trastuzumab Monotherapy for Treating Pericardial Metastasis from Breast Cancer and this Presented as Cardiac Tamponade
-
Moon HG, Jung EJ, Park ST, Song DH, Ha WS, Choi SK, Hong SC, Lee YJ, Joo YT, Jeong CY
- KMID: 2211232
- J Korean Surg Soc.
- 2008 Aug;75(2):129-133.
Although autopsy studies suggest that malignant pericardial effusion is present in up to 15% of the patients suffering with malignancies, symptomatic pericardial effusion presenting as a first manifestation of systemic... -
- CITED
-
- Close
- SHARE
-
- Close
- Targeted Therapy for Breast Cancer
-
Oh HS
- KMID: 2168204
- Hanyang Med Rev.
- 2012 May;32(2):112-117.
- doi: 10.7599/hmr.2012.32.2.112
Breast cancer is the most common cancer in women in the U.S. and Western Europe and second most common cancer in women in Korea. Targeted therapies for breast cancer are... -
- CITED
-
- Close
- SHARE
-
- Close
- The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
-
Lee JS, Son BH, Ahn SH
- KMID: 2242189
- J Breast Cancer.
- 2012 Jun;15(2):189-196.
- doi: 10.4048/jbc.2012.15.2.189
PURPOSE: Little information exists about the possible influence of serum HER2/neu on response to chemotherapy. We propose that the assessment of serum HER2/neu in a pretreatment serum sample may be... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer
-
Yoon HJ, Kim KH, Kim JY, Park HJ, Cho JY, Hong YJ, Park HW, Kim JH, Ahn Y, Jeong MH, Cho JG, Park JC
- KMID: 2362926
- J Breast Cancer.
- 2016 Dec;19(4):402-409.
- doi: 10.4048/jbc.2016.19.4.402
PURPOSE: As the numbers of cancer cases and survivors increase, the incidence and natural history of chemotherapy-induced cardiotoxicities in patients with breast cancer may also be expected to change. The... -
- CITED
-
- Close
- SHARE
-
- Close
- Optimization of ultrasound parameters for microbubble-nanoliposome complex-mediated delivery
-
Yoon YI, Yoon TJ, Lee HJ
- KMID: 2381997
- Ultrasonography.
- 2015 Oct;34(4):297-303.
- doi: 10.14366/usg.15009
PURPOSE: The aim of this study was to identify the optimal ultrasound (US) parameters for gene and drug delivery. METHODS: In order to target SkBr3, which is a breast cancer cell... -
- CITED
-
- Close
- SHARE
-
- Close
- Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
-
Kim EK, Cho J, Kim JY, Chang SA, Park SJ, Choi JO, Lee SC, Ahn JS, Park SW, Im YH, Jeon ES, Park YH
- KMID: 2464418
- Cancer Res Treat.
- 2019 Apr;51(2):727-736.
- doi: 10.4143/crt.2018.262
PURPOSE: While concerns regarding trastuzumab-related cardiac dysfunction (TRCD) in patients with breast cancer are increasing, there is a lack of evidence supporting the current recommendations for TRCD monitoring. We aimed... -
- CITED
-
- Close
- SHARE
-
- Close
- Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment
-
Koo T, Kim IA
- KMID: 2316750
- Radiat Oncol J.
- 2016 Mar;34(1):1-9.
- doi: 10.3857/roj.2016.34.1.1
Overexpression of human epidermal growth factor receptor 2 (HER2) is found in about 20% of breast cancer patients. With treatment using trastuzumab, an anti-HER2 monoclonal antibody, systemic control is improved.... -
- CITED
-
- Close
- SHARE
-
- Close
- FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment
-
Chae H, Yoo C, Yoon JA, Lee HJ, Kim KP, Kim JE, Ahn JH, Jung KH, Gong G, Kim SB
- KMID: 2441867
- J Breast Cancer.
- 2018 Mar;21(1):45-50.
- doi: 10.4048/jbc.2018.21.1.45
PURPOSE: The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating... -
- CITED
-
- Close
- SHARE
-
- Close
- Inhibition of EGFR and HER2 in Tamoxifen-resistant T47D:A18/4-OHT Breast Cancer Cells
-
Won YS, Joo JH, Kim JS, Oh SJ, Song BJ, Jeon HM, Jung SS, Park WC
- KMID: 2211141
- J Korean Surg Soc.
- 2008 Apr;74(4):255-260.
PURPOSE: Tamoxifen has been prescribed as a very effective hormonal agent not only for the treatment of breast cancer, but also for the prevention of the disease. The development of... -
- CITED
-
- Close
- SHARE
-
- Close
- Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy
-
Jang Y, Cho EY, Cho SY
- KMID: 2450126
- J Breast Cancer.
- 2019 Jun;22(2):336-340.
- doi: 10.4048/jbc.2019.22.e17
Mucinous carcinoma (MC) is a rare subtype of breast cancer, which is composed of tumor cells floating in the abundant extracellular mucin. This form of cancer is usually estrogen receptor/progesterone... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum HER2 as a Response Indicator to Various Chemotherapeutic Agents in Tissue HER2 Positive Metastatic Breast Cancer
-
Kong SY, Lee DH, Lee ES, Park S, Lee KS, Ro J
- KMID: 2166091
- Cancer Res Treat.
- 2006 Feb;38(1):35-39.
PURPOSE: The aim of study was to evaluate the usefulness of serum HER2 as a therapeutic response indicator in patients with HER2 positive metastatic breast cancer (MBC). MATERIALS AND METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment for unresectable gastric cancer
-
Kim TY, Oh DY, Bang YJ
- KMID: 2194941
- J Korean Med Assoc.
- 2015 Mar;58(3):209-215.
- doi: 10.5124/jkma.2015.58.3.209
Systemic chemotherapy is the cornerstone of treatment for patients with advanced gastric cancer. The combination of fluoropyrimidine and platinum is the most widely used first-line treatment worldwide. In patients with... -
- CITED
-
- Close
- SHARE
-
- Close
